RNA
NASD Atrium Therapeutics, Inc.$8.50 ↑ +0.10 (+1.19%) Trading Up from the previous close of $8.40, and at the day’s high of $8.50
- YTD change
- -88.22%
- vs 20-day SMA
- -2.93%
- vs 200-day SMA
- -67.32%
Price ranges
Price & Performance
-5.46 (-39.80%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 88.4% away from all-time highs of $73.06
- RNA is down 88% since the beginning of the year
- RNA is down 83% over the past 12 months
- RNA is down 18% over the past 1 month
- 20% of all RNA investors are betting against RNA
RNA reads neutral: price sits below both the 20- and 200-day averages, the 12-month move is -83.7%.
- Previous minute
- +$0.00
- Last hour
- +$0.10
- Last 5 days
- +4.42%
- vs 8-day SMA
- +4.89%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Atrium Therapeutics, Inc. operates as a biopharmaceutical company that provides RNA therapeutics services to the heart to transform the standard of care for people living with cardiomyopathies. Its products pipeline includes two lead development candidates: ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both conditions are severe, life-threatening, rare autosomal dominant progressive cardiomyopathies with no approved treatment options and high unmet need. The company was founded on September 30, 2025 and is headquartered in San Diego, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
